As enrollment in Medicare Advantage is expected to increase to a new all-time high for the sixth year in a row, CMS announced that Medicare Advantage premiums will remain stable in 2016.
As enrollment in Medicare Advantage (MA) is expected to increase to a new all-time high for the sixth year in a row, CMS announced that MA premiums will remain stable in 2016.
According to new information from CMS, the average MA premium will decrease from $32.91 in 2015 to $32.60 in 2016. Overall, 59% of enrollees will face no premium increase at all.
“Seniors and people with disabilities continue to experience stable premiums in Medicare health and drug plans while benefiting from a transparent and competitive marketplace,” Sean Cavanaugh, CMS deputy administrator and director of the Center for Medicare, said in a statement. “Medicare Advantage and prescription drug plans remain affordable and provide high quality care.”
Since the passage of the Affordable Care Act in 2010, MA premiums are expected to have decreased nearly 10% while enrollment increases by more than 50%. At approximately 17.4 million enrollees, MA represents one-third of the Medicare population.
Nearly two-thirds of MA enrollees are in plans with at least 4 stars for 2016, an indication that beneficiaries are receiving higher quality care—in 2009 just 17% of enrollees were in plans with 4 or more stars.
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
2 Commerce Drive
Cranbury, NJ 08512